Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention

Edouard Cheneau, Daniel Canos, Pramod K. Kuchulakanti, Seung-Woon Rha, Lowell F. Satler, William O. Suddath, Kenneth M. Kent, Augusto D. Pichard, Ron Waksman

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Anticoagulation during percutaneous coronary intervention (PCI) requires the monitoring of activated clotting time (ACT) to protect from periprocedural ischemic and bleeding complications; however, the optimal ACT values have not been established when PCI is performed with bivalirudin. After 495 consecutive patients treated for coronary artery disease with PCI received bivalirudin as a single anticoagulation agent, it was found that ACT is reproducible when bivalirudin is used during PCI and does not correlate with clinical events.

Original languageEnglish
Pages (from-to)789-792
Number of pages4
JournalAmerican Journal of Cardiology
Volume94
Issue number6
DOIs
Publication statusPublished - 2004 Sep 15
Externally publishedYes

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Value of monitoring activated clotting time when bivalirudin is used as the sole anticoagulation agent for percutaneous coronary intervention'. Together they form a unique fingerprint.

  • Cite this